CVS Health said Wednesday it will break itself into two independent public companies, separating its roughly 9,000 retail pharmacies from the Aetna insurance and Caremark pharmacy-benefits businesses it spent a decade stitching together. The announcement, made alongside third-quarter results that beat Wall Street's estimates, marks a reversal for a company that walked away from the same idea just two years ago.
Under the plan, detailed in a securities filing outlining the separation, one company will keep the CVS Health name and house Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, to be called CVS Pharmacy, will take the roughly 9,000 stores, mail-order pharmacy, MinuteClinic and the Health100 technology unit. Chief executive David Joyner will run the healthcare-solutions company; group president Prem Shah will become CEO of CVS Pharmacy. Together the businesses now serve about 87 million pharmacy-benefit plan members, 37 million insurance customers and employ nearly 30,000 pharmacists. The companies expect to complete the split in the first half of 2028, pending board sign-off and an effective registration statement with the SEC, and the transaction is structured to be tax-free to shareholders.
A reversal from 2024
CVS considered an almost identical breakup in October 2024 and shelved it. At the time, Joyner argued the company was mid-turnaround and lacked the cash and operating stability to execute a split responsibly. Management says that calculus has changed: CVS has beaten earnings estimates for eight straight quarters, cut roughly $2 billion in costs, closed underperforming stores and lifted expected 2026 operating cash flow to at least $15.5 billion, up from $9.1 billion in 2024. The company also hit its debt-reduction targets ahead of schedule.
"Our history has been defined by proactively evolving to stay ahead of what's next in healthcare," Joyner said in the announcement, framing the split as a move to sharpen each business's focus on consumers rather than a response to distress. He told reporters the decision was not driven by the regulatory scrutiny facing pharmacy-benefit managers like Caremark, even as several states pursue new restrictions on PBM practices.
Skepticism on Wall Street
Investors were less convinced: CVS shares fell roughly 12% on the news, a sharper reaction than the operational improvements alone would suggest. Analysts flagged unresolved questions about how independent the two companies will really be — Joyner has said cross-company synergies will be "preserved in commercial agreements" the businesses plan to negotiate over the next 15 to 18 months. Jefferies analyst Brian Tanquilut noted that a standalone retail pharmacy once looked "unthinkable" and cautioned that some of its recent strength reflects rivals closing stores rather than durable demand. Leerink's Michael Cherny questioned whether a freestanding PBM and insurer can keep the pricing advantages that come from common ownership once outside lawsuits and new contracts intervene, while RBC's Ben Hendrix warned that losing retail pharmacists' role in patient outreach could hurt Aetna's Medicare Advantage quality scores. The scale of the reaction was still being tallied hours later, when a separate newsroom tracked the selloff in real time, watching it erase billions in market value within hours of the announcement.
The split unwinds the logic behind CVS's $70 billion acquisition of Aetna in 2018, when executives argued that combining a pharmacy chain, insurer and drug-benefits manager under one roof would better coordinate patient care. Retail pharmacy margins remain thin, in the mid-single digits, and Caremark still faces pressure from potential changes to the federal 340B drug-discount program next year. CVS says both resulting companies are expected to carry solid investment-grade credit ratings at separation, with Goldman Sachs and Consello advising on the deal and Wachtell, Lipton, Rosen & Katz as legal counsel.
What happens next hinges on the Form 10 registration CVS must file with the SEC and on how convincingly the two sides translate "commercial agreements" into contracts that keep pharmacies, insurance and drug benefits working together even after the corporate ties are cut.
